NCT07090759招募中3 期
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Trial of GST-HG141（Neracorvir）for Combination Therapy (add-on) in Patients With Inadequate Response to Antiviral Drugs in Chronic Hepatitis B (CHB)
Fujian Akeylink Biotechnology Co., Ltd.2 个研究点 分布在 1 个国家目标入组 526 人开始时间: 2025年7月24日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 526
- 试验地点
- 2
- 主要终点
- Proportion of participants with serum Hepatitis B Virus (HBV) DNA
研究概览
简要总结
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
详细描述
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.
This research project enrolled a total of 526 CHB patients who have an inadequate response to hepatitis B antiviral treatment. They were divided into two groups, with 263 patients in each group.
The qualified participants were randomly assigned to the GST-HG141 group and the placebo group at a ratio of 1:1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female individuals aged 18-70 years (inclusive of the boundaries);
- •Male weight ≥ 50 kg, female weight ≥ 45 kg, with a body mass index (BMI) within the range of 18-35 kg/m2 (inclusive of the boundaries);
- •Have been continuously taking nucleoside analogues (entecavir [ETV], tenofovir disoproxil fumarate [TDF], emivirofavir [TMF], or propivirofavir [TAF]) for more than one year (with a break of less than one month in the past year), and are receiving treatment at the time of screening and agree to accept the treatment plan provided by this study during the study period;
- •* Have maintained the same NA monotherapy for more than 3 months before screening
- •HBeAg positive, serum HBV DNA can be detected by high-sensitivity PCR, and HBV DNA > 50 IU/mL;
- •At the time of screening, ALT ≤ 5×ULN;
- •Male participants with a fertile female partner or female participants of childbearing age who are willing to voluntarily take effective contraceptive measures from the time of screening until 28 days after the completion of the study ;
- •Sign the informed consent form before the trial and be able to complete the study as required by the trial protocol.
排除标准
- •History of life-threatening severe allergic reactions such as anaphylactic shock, or allergy to the active ingredients or excipients of the study drug as suspected by the investigator;
- •Concomitant use of cytochrome P450 enzyme 3A4 (CYP3A4) inhibitors, inducers, or substrates within 28 days prior to screening;
- •Systemic use of immunosuppressants, immunomodulators (interferon must be discontinued for more than 12 months), or cytotoxic drugs within 6 months prior to screening; or vaccination with live attenuated vaccines within 1 month prior to screening;
- •Presence of acute infections requiring treatment prior to randomization;
- •Clinically significant acute or chronic liver disease not caused by HBV infection, rendering the subject unsuitable for participating in the study as determined by the investigator;
- •Subjects with a history of cirrhosis (e.g., subjects who have undergone pathological examination of liver tissue with a report indicating cirrhosis or those who have undergone endoscopy indicating esophageal or gastric varices); or subjects with currently diagnosed or suspected decompensated cirrhosis, including but not limited to: hepatic encephalopathy, hepatorenal syndrome, bleeding from esophageal or gastric varices, splenomegaly, and ascites; or subjects with significant progression of liver fibrosis;
- •Primary liver cancer; serum alpha-fetoprotein (AFP) greater than 20 μg/L (or 20 ng/mL) or DCP>40 mAU/mL or imaging suggesting possible malignant lesions in the liver; concurrent other malignancies or history of other malignancies within the past 5 years (except for cured basal cell carcinoma or squamous cell carcinoma of the skin and cervical carcinoma in situ);
- •Presence of gastrointestinal impairment or gastrointestinal disease that may affect the absorption of oral medication in the judgment of the investigator, such as severe gastrointestinal diseases (peptic ulcer, erosive or atrophic gastritis), partial gastrectomy, Grade > 2 gastrointestinal symptoms at screening (e.g., nausea, vomiting, or diarrhea), etc.;
- •Concurrent severe diseases of the circulatory, respiratory, urinary, hematologic, metabolic, immune, psychiatric, neurological, renal, or other systems, rendering the subject unsuitable for participating in the study as determined by the investigator.
- •Subjects with major trauma or major surgery within 3 months prior to screening; or those who plan to undergo surgery during the study period;
- •Laboratory tests:
- •Platelet count < 100 × 109/L;
- •White blood cell count < 3.0 × 109/L;
- •Absolute neutrophil count < 1.3 × 109/L;
- •Serum total bilirubin > 2× ULN;
- •Albumin < 35 g/L;
- •GFR ≤ 60 mL·min-1·(1.73 m2)-1 (calculated using the CKD-EPI formula);
- •International normalized ratio (INR) of prothrombin time >1.5;
- •Positive for hepatitis C antibody, positive for HIV antigen/antibody, or positive for syphilis antibody with a positive RPR or TRUST test result;
- •History of sustained alcohol abuse within the past 3 years (weekly alcohol intake > 14 units, where 1 unit of alcohol equals 1 bottle of 350 mL beer, 120 mL wine, or 30 mL of spirits at 40% alcohol content);
- •History of drug dependence or substance abuse;
- •Participation in clinical trials involving other investigational drugs or medical devices and receiving the investigational drug or using the medical device within 3 months prior to screening;
- •Women who are breastfeeding or tested positive for pregnancy;
- •Determined by the investigator to be unsuitable for this trial for any other reasons.
研究组 & 干预措施
GST-HG141
Experimental
干预措施: GST-HG141 (Drug)
GST-HG141 Placebo
Placebo Comparator
干预措施: GST-HG141 Placebo (Drug)
结局指标
主要结局
Proportion of participants with serum Hepatitis B Virus (HBV) DNA
时间窗: Up to 48 weeks
Proportion of participants with serum Hepatitis B Virus (HBV) DNA \< lower limit of quantification (LLOQ) treatment period;
次要结局
- Serum HBV DNA(Up to 48 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical TrialChemotherapy-induced Peripheral NeuropathyColorectal CancerNCT04690283Nanjing NingQi Medicine Science and Technology Co., Ltd.360
已完成
3 期
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCStage II-III Non-small Cell Lung CancerNCT04158440Shanghai Junshi Bioscience Co., Ltd.501
招募中
3 期
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast CancerNCT06994507Qilu Pharmaceutical Co., Ltd.352
招募中
3 期
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine TherapyNCT06998108BeBetter Med Inc330
已完成
3 期
A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing SpondylitisAnkylosing SpondylitisNCT06378697Akeso510